Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-06-14

DOI:

10.1016/s1470-2045(25)00198-6

Affiliations:

37

Authors:

41

Go to article

Institutions	Authors	Share
CStone Pharmaceuticals, China	6.000000	0.15
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.02
Shengjing Hospital of China Medical University, China	1.000000	0.02
Beijing Hospital, China	1.000000	0.02
First Affiliated Hospital, ZZU, China	1.000000	0.02
The First People's Hospital of Hangzhou, China	1.000000	0.02
Jinan Central Hospital, China	1.000000	0.02
The First Affiliated Hospital of Dalian Medical University, China	1.000000	0.02
Sichuan Cancer Hospital, China	1.000000	0.02
Second Affiliated Hospital, AHMU, China	1.000000	0.02
Suzhou Municipal Hospital, China	1.000000	0.02
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.02
Tianjin Medical University Cancer Institute and Hospital, TMU, China	1.000000	0.02
The First Hospital of China Medical University, China	1.000000	0.02
Peking University Third Hospital (PUTH), PKUHSC, China	1.000000	0.02
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), China	1.000000	0.02
Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University), China	1.000000	0.02
Yantai Yuhuangding Hospital, China	1.000000	0.02
Harbin Medical University Cancer Hospital, China	1.000000	0.02
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.02
Liaoning Cancer Hospital and Institute, China	1.000000	0.02
The First Affiliated Hospital, USTC, China	1.000000	0.02
Hunan Cancer Hospital, China	1.000000	0.02
Henan Cancer Hospital, ZZU, China	1.000000	0.02
First Affiliated Hospital, AHMU, China	1.000000	0.02
The Second Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.02
The First Hospital of Jilin University, China	1.000000	0.02
The Affiliated Hospital of Qingdao University, China	1.000000	0.02
The Second Hospital of Dalian Medical University, China	1.000000	0.02
Second Xiangya Hospital, CSU, China	1.000000	0.02
Fujian Cancer Hospital, China	1.000000	0.02
Xinjiang Tumor Hospital, XJMU, China	1.000000	0.02
The First Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.02
Liuzhou People's Hospital, China	1.000000	0.02
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.02
Shanghai Pulmonary Hospital, China	0.500000	0.01
Shanghai East Hospital, Tongji University, China	0.500000	0.01

Interested in Oncology and Carcinogenesis?